Clinical Trials Logo
  1. Home
  2. Blood Platelet Disorders
  3. NCT01133860

Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

Blood Platelet Disorders Clinical Trial

Official title:
An Exploratory Phase II Dose Escalation Study of Eltrombopag in MYH9 Related Disease

Clinical Trial Summary

The term MYH9-related disease (MYH9RD) includes four genetic disorders: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome. All these disorders derive from mutation of a unique gene, named MYH9, and they have been recognized as different clinical presentations of a single illness that was named MYH9RD. All patients affected by MYH9RD present since birth with thrombocytopenia, which can result in a variable degree of bleeding diathesis; some of them subsequently develop additional clinical manifestations, such as renal damage, sensorineural hearing loss, and/or presenile cataracts. Eltrombopag is an oral thrombopoietin receptor agonist that stimulates proliferation and differentiation of megakaryocytes, the bone marrow cells that produce blood platelets. This drug is effective in increasing platelet count in healthy volunteers, as well as in patients affected by some acquired thrombocytopenias, such as idiopathic thrombocytopenic purpura and HCV related thrombocytopenia. The purpose of this study is to determine if eltrombopag, administered orally at the dose of 50 or 75 mg/daily for up to 6 weeks, is effective in increasing platelet count of patients affected by MYH9RD. Further aims of this study are to test if eltrombopag is effective in reducing bleeding tendency of MYH9RD patients; to evaluate safety and tolerability of eltrombopag in patients with MYH9RD; to evaluate in vitro function of platelets produced during therapy in patients responding to this drug.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01133860
Study type Interventional
Source IRCCS Policlinico S. Matteo
Contact
Status Completed
Phase Phase 2
Start date January 2009
Completion date June 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00168090 - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Phase 4
Completed NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Phase 1/Phase 2
Completed NCT02135575 - Effects of Exercise Training on Cardiovascular Health in Middle-aged Women N/A
Completed NCT00115375 - Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO) Phase 2
Completed NCT00111215 - Treatment and Management of Women With Bleeding Disorders N/A
Recruiting NCT02711124 - Relationship Between Level of Hemoglonin A1c and Platelet Function in Patients Undergoing Cardiac Surgery N/A
Completed NCT02217553 - The Effect of Vitamin D Supplementation on HIV-associated Platelet Hyperreactivity N/A
Terminated NCT00359398 - Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery Phase 2
Terminated NCT00334204 - Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy? Phase 4